Moacyr Ribeiro de Oliveira

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

C. Rudin, G. Shapiro, D. Camidge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, M. Ranson, 2012, Clinical Cancer Research.